Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

10.1245/ASO.2005.02.029
Annals of Surgical Oncology 12:246-253 (2005)
© 2005 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neri, A.
Right arrow Articles by Pinto, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neri, A.
Right arrow Articles by Pinto, E.

Original Article

Prognostic Value of Extracapsular Extension of Axillary Lymph Node Metastases in T1 to T3 Breast Cancer

Alessandro Neri, MD1, Daniele Marrelli, MD1, Franco Roviello, MD1, Alfonso De Stefano, MD1, Alfredo Guarnieri, MD2, Eleonora Pallucca, MD2 and Enrico Pinto, MD1

1 Department of General Surgery and Surgical Oncology, Surgical Oncology Unit, University of Siena, Policlinico Le Scotte, V. le Bracci, 53100 Siena, Italy
2 General Surgery Unit, University of Siena, Policlinico Le Scotte, V. le Bracci, 53100 Siena, Italy

Correspondence: Address correspondence and reprint requests to: Alessandro Neri, MD; E-mail: neria{at}unisi.it.

Background: The importance of extracapsular extension (ECE) of axillary metastases as a risk factor for either local or distant recurrence and poorer survival in breast cancer has been suggested, but its prognostic value has not been uniformly confirmed.

Methods: From a prospective database including 1142 breast cancer patients operated on at the Department of General Surgery and Surgical Oncology of the University of Siena, we selected 376 cases with pT1 to pT3 node-positive breast cancer. The prognostic significance of ECE of axillary metastases was evaluated with respect to disease-free survival, overall survival, and the patterns of disease recurrence. Such prognostic significance was then compared with that of other clinical and pathologic factors.

Results: With a median follow-up of 103 months, factors with independent prognostic value for disease-free survival by multivariate analysis included absence of estrogen receptors (P < .0005), pN category (P < .01), presence of lymphovascular invasion (LVI; P < .005), and ECE (P < .0001). An independent negative prognostic effect on overall survival was observed for absence of estrogen and progesterone receptors (P < .05), pN category (P < .05), and presence of LVI (P < .005) and ECE (P < .0001). The presence of ECE was significantly related to an increased risk of regional (13.4% vs. 6.6%; P = .037) and distant (43% vs. 16.2%; P < .001) recurrences.

Conclusions: ECE demonstrated a stronger statistical significance in predicting prognosis than the pN category and was also related to an increased risk of distant recurrences. We suggest that the decision on adjuvant therapy should consider the presence of ECE of axillary metastases and peritumoral LVI as indicators of high biological aggressiveness.

Key Words: Breast neoplasm • Axilla • Lymphatic metastases • Prognosis • Multivariate analysis • Prospective studies




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
J. H. Chen, G. Agrawal, P. Carpenter, R. S. Mehta, O. Nalcioglu, and M.-Y. Su
Pathological Axillary Lymph Node Status in HER-2 Receptor Positive and Negative Breast Cancers
Ann. Surg. Oncol., March 1, 2008; 15(3): 941 - 942.
[Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
G Cserni
Axillary sentinel lymph node micrometastases with extracapsular extension: a distinct pattern of breast cancer metastasis?
J. Clin. Pathol., January 1, 2008; 61(1): 115 - 118.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society of Surgical Oncology.